Bristol-Myers Squibb Company

Release Summary

Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Bristol-Myers Squibb Company